Prognostic Significance of Pretreatment Derived Hematological Markers and Serum Biochemical Parameters on the Overall Survival Rate in Individuals Diagnosed with Cervical Cancer Undergoing Curative Surgery

Authors

Edakkadath Raghavan Sindhu  1 , Keloth Erakodan Greeshma  2 , Nandhini Devi  3 , Mohandoss Murugesan  4 , Kalpita Shringapure  5 , DSA Karthickeyan  6
Division of Biochemistry, Department of Clinical Laboratory Services and Translational Research, Malabar Cancer Centre (Postgraduate Institute of Oncology Sciences and Research), Kannur, Kerala, India. 1 , Department of Radiation Oncology, Malabar Cancer Centre (Postgraduate Institute of Oncology Sciences and Research), Kannur, Kerala, India. 2 , Department of Medical Oncology, Malabar Cancer Centre (Postgraduate Institute of Oncology Sciences and Research), Kannur, Kerala, India. 3 , Division of Transfusion Medicine, Malabar Cancer Centre (Postgraduate Institute of Oncology Sciences and Research), Thalassery, Kerala, India. 4 , Department of Preventive and Social Medicine, Medical College Baroda, Vadodara, Gujarat, India. 5 , Academy for Public Health, Kozhikode, Kerala, India. 6
“crossref”/
Views: 0  
Downloads: 0  

##plugins.themes.bootstrap3.article.main##

Abstract

Objectives: This study aims to evaluate the prognostic value of pretreatment hematological and biochemical markers, including serum albumin, globulin, and alkaline phosphatase, on overall survival in cervical cancer patients who have undergone curative surgery. Materials and Methods: This retrospective cohort study was conducted at Malabar Cancer Centre, Kerala, analyzing data from cervical cancer patients in FIGO stage 1, who underwent surgery between January 2018 and February 2024. Key hematological and biochemical parameters were evaluated, and Kaplan-Meier analysis was performed to assess overall survival, with statistical significance set at p < 0.05. Results: The study analyzed the overall survival of 35 cervical cancer patients in relation to hematological indices such as LMR, NLR, PLR, MPVP and ALBALKP, along with the impact of co-morbidities and FIGO staging. Statistical analysis revealed no significant differences in survival outcomes across different LMR, NLR, PLR, MPVP and ALBALKP groups (p > 0.05). Additionally, FIGO staging showed that most cases were diagnosed in early invasive stages, and co-morbidities like diabetes and hypertension were common among patients. Conclusion: Tumor stage and co-morbid conditions significantly influenced survival markers LMR, NLR, PLR, MPVP, and ALBALKP showed no statistically significant association, highlighting the need for further research with larger cohorts to confirm their prognostic value.

##plugins.themes.bootstrap3.article.details##

Prognostic Significance of Pretreatment Derived Hematological Markers and Serum Biochemical Parameters on the Overall Survival Rate in Individuals Diagnosed with Cervical Cancer Undergoing Curative Surgery. (2026). Annals of Medicine and Medical Sciences, 201-207. https://doi.org/10.5281/
Original Article

Copyright (c) 2026 Edakkadath Raghavan Sindhu, Keloth Erakodan Greeshma, Nandhini Devi, Mohandoss Murugesan, Kalpita Shringapure, DSA Karthickeyan

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License All articles published in Annals of Medicine and Medical Sciences are licensed under a Creative Commons Attribution 4.0 International License.

[1] Mayadev JS, Ke G, Mahantshetty U, Pereira MD, Tarnawski R, Toita T. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. Int J Gynecol Cancer 2022; 32: 436–445. doi: 10.1136/ijgc-2021-003013

[2] Kalliala I, Athanasiou A, Veroniki AA, Salanti G, Efthimiou O, Raftis N, et al. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol 2020; 31: 213–227. doi: 10.1016/j.annonc.2019.11.004

[3] Endo D, Todo Y, Okamoto K, Minobe S, Kato H, Nishiyama N. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: A retrospective analysis in a japanese cohort. J Gynecol Oncol 2015; 26: 12–18. doi: 10.3802/jgo.2015.26.1.12

[4] Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860–867. doi: 10.1038/nature01322

[5] Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009; 197: 466–472. doi: 10.1016/j.amjsurg.2007.12.057

[6] Leitch EF, Chakrabarti M, Crozier J, Mckee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007; 97: 1266–1270. doi: 10.1038/sj.bjc.6604027

[7] Chen L, Sheng XG, Zhang SQ, Chen YT, Liu BW. Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil Lymphocyte. Medicine (Baltimore) 2016; 95: e4381. doi: 10.1097/MD.0000000000004381

[8] Oymak E, Guler OC, Onal C. Prognostic significance of albumin and globulin levels in cervical cancer patients treated with chemoradiotherapy. Int J Gynecol Cancer 2023; 33: 19–25. doi: 10.1136/ijgc-2022-003842

[9] Medeiros Guimarães Y, Godoy LR, Longatto-Filho A, Dos Reis R. Management of Early-Stage Cervical Cancer: A Literature Review. Cancers (Basel) 2022; 14: 575. doi: 10.3390/cancers14030575

[10] Pedrazzani C, Mantovani G, Fernandes E, Bagante F, Luca Salvagno G, Surci N, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep 2017; 7: 1494. doi: 10.1038/s41598-017-01652-0

[11] Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: Systematic review and meta-analysis. Br J Cancer 2014; 110: 1595–1605. doi: 10.1038/bjc.2014.46

[12] Chen XQ, Xue CR, Hou P, Lin BQ, Zhang JR. Lymphocyte-to-monocyte ratio effectively predicts survival outcome of patients with obstructive colorectal cancer. World J Gastroenterol 2019; 25: 4970–4984. doi: 10.3748/wjg.v25.i33.4970

[13] Inamoto S, Kawada K, Okamura R, Hida K, Sakai Y. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study. Int J Colorectal Dis 2019; 34: 1303–1315. doi: 10.1007/s00384-019-03306-x

[14] Wu YY, Zhang X, Qin YY, Qin JQ, Lin FQ. Mean platelet volume/platelet count ratio in colorectal cancer: A retrospective clinical study. BMC Cancer 2019; 19: 314. doi: 10.1186/s12885-019-5464-x

[15] Onal C, Gultekin M, Yavas G, Oymak E, Yuce Sari S, Guler OC, et al. The impact of serum albumin-to-alkaline phosphatase ratio in cervical cancer patients treated with definitive chemoradiotherapy. J Obstet Gynaecol 2022; 42: 2426–2432. doi: 10.1080/01443615.2022.2084334

[16] Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: A global health crisis. Cancer 2017; 123: 2404–2412. doi: 10.1002/cncr.30667

[17] Landoni F, Maneo A, Cormio G, Perego P, Milani R, Caruso O, et al. Class II versus Class III Radical Hysterectomy in Stage IB–IIA Cervical Cancer: A Prospective Randomized Study. Gynecol Oncol 2001; 80: 3–12. doi: 10.1006/gyno.2000.6011

[18] Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999; 73: 177–183. doi: 10.1006/gyno.1999.5387

[19] Cofie LE, Hirth JM, Wong R. Chronic comorbidities and cervical cancer screening and adherence among US-born and foreign-born women. Cancer Causes Control 2018; 29: 1105–1112. doi: 10.1007/s10552-018-1084-8

[20] Wan L, Wu C, Luo S, Xie X. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors. Dis Markers 2022; 2022: 3610038. doi: 10.1155/2022/3610038

[21] Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev 2019; 20: 863–868. doi: 10.31557/APJCP.2019.20.3.863

[22] Deng Q, Long Q, Liu Y, Yang Z, Du Y, Chen X. Prognostic value of preoperative peripheral blood mean platelet volume/platelet count ratio (MPV/PC) in patients with resectable cervical cancer. BMC Cancer 2021; 21: 648. doi: 10.1186/s12885-021-08412-1

[23] Zhang K, Dong S, Jing YH, Gao HF, Chen LY, Hua YQ, et al. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. BMC Cancer 2020; 20: 541. doi: 10.1186/s12885-020-07018-7

[24] Wang Y, Xiong F, Yang J, Xia T, Jia Z, Shen J, et al. Decreased albumin-to-alkaline phosphatase ratio predicted poor survival of resectable gastric cancer patients. J Gastrointest Oncol 2021; 12: 1338–1348. doi: 10.21037/jgo-21-364

Similar Articles

1-10 of 82

You may also start an advanced similarity search for this article.